Under breakthrough therapy designation, FDA approves chronic lymphocytic leukemia drug
November 1st 2013FDA has approved obinutuzumab (Gazyva, Genentech, a member of the Roche Group), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of patients with previously untreated chronic lymphocytic leukemia.
Allopurinol alone found inadequate for gout control
October 31st 2013Allopurinol, considered the standard of care for gout, may be inadequate to lower uric acid levels in patients with gout, according to new safety and efficacy data from a large study presented at the American College of Rheumatology 2013 annual meeting recently in San Diego, Calif.
Bullying, disrespect rampant in healthcare settings
October 29th 2013Rude and disrespectful behavior including bullying and intimidation is a big problem in healthcare workplaces that erodes professional communication essential to patient safety, according to a recent study by the Institute for Safe Medication Practices.
FDA approves extended-release, single-entity hydrocodone product
October 29th 2013FDA has approved hydrocodone bitartrate extended-release capsules (Zohydro ER, Zogenix) for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate.
Study highlights need to address anaphylaxis prevention
October 24th 2013Severe life-threatening allergic reactions are more common than many thought. Anaphylaxis very likely occurs in nearly 1 in 50 Americans (1.6%), and the rate is probably higher, close to 1 in 20 (5.1%), according to a study published in the Journal of Allergy and Clinical Immunology.
FDA calls for reclassification of hydrocodone products to Schedule II
October 24th 2013The FDA is recommending to the U.S. Department of Health and Human Services (HHS) that hydrodone combination products, such as Vicodin, be reclassified as a Schedule II product, placing tighter controls on the pain medications. Hydrocodone is currently a Schedule III drug, according to an FDA announcement.
Antibiotics overprescribed for sore throats, bronchitis
October 21st 2013Vast majorities of people who see physicians for sore throats or acute bronchitis receive antibiotics, yet only a small percentage should, according to analyses of 2 major national surveys presented recently at the IDWeek Meeting in San Francisco
Rivaroxaban reduced hospitalization by 1 day in pulmonary embolism cases
October 16th 2013In the treatment of pulmonary embolism (PE) in North American patients, rivaroxaban (Xarelto) reduced length of hospital stay by 1 full day compared to conventional dual therapy, according to data presented at the American College of Emergency Physicians scientific assembly, October 14-17, in Seattle.
More independent pharmacies offer patient services in challenging healthcare environment
October 16th 2013"Because of poor medication adherence, the rampant prescription drug abuse problem, and the worsening primary care shortage, pharmacists are ideally situated,” says B. Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association.